Europe's clinical AI search market is no longer hypothetical. Multiple tools with different strategies, different regulatory postures, and different geographic focuses are now competing for clinician adoption. The market has moved from "interesting experiment" to "investable category."
OpenEvidence Proved Demand in the US
OpenEvidence established that clinicians want fast, cited, source-grounded medical answers — and that the demand is large enough to support a $12 billion company. Reuters reported daily use by more than 40% of US physicians across 10,000 hospitals, approximately 18 million consultations in December 2025 alone, and $100 million in annualised revenue from pharmaceutical advertising.
Its reported withdrawal from the UK and EU in April 2026 — citing regulatory uncertainty around the EU AI Act — creates a narrative vacuum in Europe. The demand OpenEvidence proved is not US-specific. European clinicians want the same thing. The question is who builds it for European practice.
DR.INFO Shows the European Regulatory/Reference Route
DR.INFO takes a different approach from OpenEvidence. Where OpenEvidence built for US scale and speed, DR.INFO has built for European regulatory compliance and professional-use boundaries. CE-marked under EU MDR 2017/745. EU-hosted. GDPR-aligned. EU AI Act compliant. Multilingual (12+ European languages). Published pilot study in Cureus with 29 physicians across Portuguese institutions.
DR.INFO's positioning is explicitly European — and explicitly regulated. This matters because European healthcare procurement increasingly requires evidence of regulatory compliance that US-first tools may not provide. DR.INFO is not trying to be the European OpenEvidence; it is trying to be the European clinical reference tool that passes procurement scrutiny.
Praxis Shows the Venture-Backed UK Clinical Search Route
Praxis Medicine takes yet another approach. Where DR.INFO leads with regulatory posture, Praxis leads with founder and investor signal — Douglas Stark (Voi co-founder), Balderton Capital, Creandum, 70 million SEK raised. Praxis has positioned publicly as a UK-only clinical decision-support product for UK-licensed healthcare professionals, with explicit UK trusted-source grounding (NICE, CKS, NHS Digital, Europe PMC).
Praxis represents the bet that clinical AI search in Europe needs to be built country-by-country, starting with the UK — the same market entry strategy that iatroX has pursued.
Why Europe Will Split by Source, Language, and Clinical Workflow
The market is not one race. It is several overlapping races.
Medical evidence search. Tools that retrieve peer-reviewed literature — OpenEvidence's original category.
Guideline search. Tools that retrieve and synthesise national clinical guidelines — NICE/CKS in the UK, AWMF/S3 in Germany. iatroX, Praxis, Medwise, Umbil, ClariMed.
Medicines information. Drug databases, interaction checking, SmPC retrieval. DR.INFO includes drug database features. iatroX retrieves SmPC data.
Visual education. Visual abstracts, concept mapping, teaching aids. DR.INFO's visual abstract feature.
Clinical workflow. Calculators, exam preparation, CPD, referral letters, discharge summaries. iatroX's calculator and exam platform. Umbil's ward workflow tools.
Enterprise integration. EHR/EMR connection, institutional policies, SSO. DR.INFO's organisation tier. Medwise's NHS Trust deployments.
No single tool will win all six races. The winners will be those that earn repeated daily use from their target users — not those that claim the broadest feature set.
Where iatroX Fits in the UK Layer
iatroX is the UK-focused clinician workflow platform in this map — not merely another answer engine, but a place where clinical search, calculators, and learning converge. UKCA-marked, MHRA-registered. Free.
The most useful question for UK clinicians is not "which European clinical AI tool has the best regulatory label?" — it is "which tool fits UK practice, UK guidelines, and my actual clinical day?"
Try Ask iatroX for UK-focused clinical questions, calculators, and exam preparation →